CD19 and congenital rubella syndrome: In fact, in the phase I and phase II clinical trials that led to the approval of CD19‐targeted CAR T‐cell therapy, CRS of any grade was experienced by 58–92% of patients, while neurologic events of any grade were seen in 21–67% of patients who received an infusion.5, 6, 7